Lutetium Lu177 Edotreotide

Star0

DB17278InvestigationalSmall molecule

Lutetium Lu177 Edotreotide: Overview.

Mechanism: Pharmacologically active on Somatostatin receptor type 5, Somatostatin receptor type 2, and Somatostatin receptor
Curator reviewed
Formula / weight: C₆₅H₈₉LuN₁₄O₁₈S₂ · 1595.57 g/mol (avg)
Also known as: (177ludota)-toc · 177Lu-DOTATOC · 177Lu-edotreotide · Dotatoc Lu-177 · Edotreotide lutetium Lu-177

Resolves to

Compound

UNIIRGO812Q0C8CAS321835-55-6

Structure

InChIKeyXOPYQJXRGHFPOH-KIUJNHSLSA-KSMILES

[177Lu+3].C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1

Targets

P35346SSTR5P30874SSTR2

What you can answer from here — as of July 08, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lutetium Lu177 Edotreotide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account